Terbinafine-Induced Subacute Cutaneous Lupus Erythematosus
2005; Karger Publishers; Volume: 212; Issue: 1 Linguagem: Inglês
10.1159/000089024
ISSN1421-9832
AutoresDavid Farhi, M. Viguier, A. Cosnes, Pascal Reygagne, Louis Dubertret, J. Revuz, Jean‐Claude Roujeau, H. Bachelez,
Tópico(s)Cutaneous lymphoproliferative disorders research
Resumo<i>Background:</i> Nearly 10% of lupus erythematosus (LE) are drug induced. More than 60 different drugs are involved in iatrogenic LE. We report herein 3 cases of terbinafine-induced LE. <i>Observations:</i> Three patients receiving terbinafine for a suspected dermatophytic infection developed a subacute cutaneous LE, within 7 weeks following terbinafine introduction. The patients’ medical history included sicca syndrome, lung carcinoma and Kikuchi disease, respectively. Clinical remission occurred within 15 weeks following terbinafine withdrawal. <i>Discussion:</i> Sixteen cases of terbinafine-induced LE have been previously reported, including 13 women. The median age was 54 years. Prior autoimmunity was reported in 10 cases, including 5 pre-existing LE. The median delay between terbinafine introduction and LE onset was 5 weeks. The median time until clinical recovery following terbinafine withdrawal was 8 weeks. <i>Conclusion:</i> Terbinafine should be prescribed only in patients with proven dermatophytosis. We recommend cautious monitoring in patients with pre-existing autoimmunity. The diagnosis of terbinafine-induced LE should lead to the immediate and definitive withdrawal of the drug.
Referência(s)